Cosmo Pharmaceuticals NV
SIX:COPN

Watchlist Manager
Cosmo Pharmaceuticals NV Logo
Cosmo Pharmaceuticals NV
SIX:COPN
Watchlist
Price: 47.3 CHF 1.72% Market Closed
Market Cap: 829.6m CHF

Cosmo Pharmaceuticals NV
Investor Relations

Cosmo Pharmaceuticals NV, rooted in the picturesque landscapes of Italy but with its headquarters in Ireland for strategic financial maneuvering, has carved a niche for itself within the global pharmaceuticals industry. This specialty pharmaceutical company is dedicated to the development and manufacturing of therapies for gastrointestinal diseases. Cosmo’s forte lies in its proprietary clinical development platform, providing innovative solutions aimed at enhancing gastrointestinal health, covering conditions like inflammatory bowel disease, colon infections, and bowel preparation for colonoscopy. These critical health areas require specialized treatments, and Cosmo leverages its technological prowess through its novel drug delivery technologies such as Methylene Blue MMX and Aemcolo. This focus not only elevates the scientific community’s understanding of GI issues but positions Cosmo at the intersection of research innovation and practical treatment efficacy.

Cosmo Pharmaceuticals thrives on a business model that seeks to maximize the potential of its intellectual property and licensing operations. By investing substantially in research and development, the company brings forward its proprietary products which offer targeted therapies, and then participates in strategic partnerships and licensing agreements with larger pharmaceutical companies. By doing so, Cosmo reduces risk and diversifies its revenue channels. This agile strategy allows them to earn royalties and revenue through commercialization deals, placing them in a financial position of strength without having to shoulder the full burden of global marketing and distribution. The company’s ability to merge scientific ingenuity with strategic business acumen underscores its journey from a regional player to a notable name on the international pharmaceutical stage.

Show more
Loading
COPN
Swiss Market Index

Earnings Calls

2024 Q4
Feb 13, 2025
Show Transcript
Previous
Next
Strong Demand and Market Growth Ahead
2024 Q4
Feb 13, 2025

The company is optimistic about future performance, projecting a significant addressable market increase from SEK 14 billion to SEK 25 billion. They expect strong demand for their soldier communication systems, leveraging a robust order book and recent acquisition of UltraLynx, which adds SEK 1.5 billion to market estimates. The proposed dividend rises to SEK 2.30 per share, up SEK 1.30, reflecting 42% of profit after tax. The management anticipates a favorable environment with significant opportunities in the U.S. and Europe as they capitalize on competitors' exits and expand their product offerings, including high-value data hubs priced around EUR 4,000.

Show Full Analysis

Management

Mr. Alessandro E. Della Cha LL.M
Executive Chairman
No Bio Available
Mr. Niall Donnelly
Executive VP of Corporate Governance, Chief Sustainability Officer & Executive Director
No Bio Available
Mr. Giovanni Di Napoli
Chief Executive Officer & Director
No Bio Available
Mr. Mauro Severino Ajani
Founder & Non-Executive Director
No Bio Available
Ms. Svetlana Sigalova
Chief Financial Officer
No Bio Available
Mr. Marco Lecchi
Chief Operating Officer
No Bio Available
Mr. Davide Malavasi
Qualified Person & Technical Director
No Bio Available
Mr. Luigi Longo
Chief Scientific Officer
No Bio Available
Ms. Hazel Winchester
Head of Investor Relations
No Bio Available
Mr. Biagio Vigano
Chief People Officer
No Bio Available

Contacts

Address
DUBLIN
DUBLIN
Riverside II, Sir John Rogerson's Quay
Contacts
+35318170370.0
www.cosmopharma.com